Delivering precision oncology in metastatic breast cancer: Clinical impact of comprehensive genomic profiling—The <scp>CATCH</scp> experience

CATCH is a prospective precision oncology registry trial that exploits whole-genome/exome- and RNA-sequencing to enable actionable biomarker detection in metastatic breast cancer (mBC) patients of any subtype. We herein report long-term follow-up of the first 558 patients consecutively recruited into CATCH in a monocentric setting between June 2017 and October 2021. Main outcome measures were the rate of implementation of molecular tumor board (MTB) recommended treatments and treatment response as assessed by disease control rate, objective response rate and PFS ratio. Out of the recruited patients, 412 (54.9% HR+/HER2-, 31.3% TNBC, 6.8% HR-/HER2+ and 7.0% HR+/HER2+) were reviewed in the MTB. An appropriate molecularly guided anti-cancer treatment as recommended by MTB was implemented in 183 (44.4%) patients. Gene expression and computationally derived composite biomarkers further expanded treatment options in up to every second patient as compared to genomic sequencing data alone. The outcome was assessed in 152 patients and showed a Disease Control Rate (DCR) of 58.6% and an Objective Response Rate (ORR) of 27.0%. One in three patients (32.8%) showed at least a 50% longer PFS with molecularly guided therapy compared to the previous standard therapy. Notably, 86.4% of the MTB-driven implementations were off-label. CATCH highlights the impact of whole-genome/exome in combination with RNA sequencing to detect clinically relevant biomarkers in mBC. Omics-guided targeted therapy in a real-world setting allows high treatment implementation rates yielding outcome benefit for one-third of the patients.

Authors

Institutions

Publication Details

Journal
International Journal of Cancer
Published
2025-10-31
DOI
https://doi.org/10.1002/ijc.70208
Primary Topic
Cancer Genomics and Diagnostics
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Delivering precision oncology in metastatic breast cancer: Clinical impact of comprehensive genomic profiling—The CATCH experience

Hans‐Peter Sinn, Daniel Hübschmann, Celina Wagner, Stefan Fröhling et al.
International Journal of Cancer
Cancer Genomics and Diagnostics
article

Delivering precision oncology in metastatic breast cancer: Clinical impact of comprehensive genomic profiling—The CATCH experience

Hans‐Peter Sinn, Daniel Hübschmann, Celina Wagner, Stefan Fröhling, Laura L. Michel, Christoph Springfeld, Lars Buschhorn, Fangyoumin Feng, Christel C. Herold‐Mende, Albrecht Stenzinger, Katrin Pfütze, Nicola Dikow, Mario Hlevnjak, Stephan Wolf, Sabine Heublein, Carlo Fremd, Polina Y. Kozyulina, Richard F. Schlenk, Katharina Smetanay, Marc Zapatka, Steffen Hirsch, Verena Thewes, Oliver Zivanovic, Andreas Trumpp, Andreas Schneeweiß, Constantin Pixberg, Lena Jassowicz, Chen Hong, Christian Maurer, Peter Lichter, Dirk Jäger, Lukas Wagener
article en

Abstract

CATCH is a prospective precision oncology registry trial that exploits whole-genome/exome- and RNA-sequencing to enable actionable biomarker detection in metastatic breast cancer (mBC) patients of any subtype. We herein report long-term follow-up of the first 558 patients consecutively recruited into CATCH in a monocentric setting between June 2017 and October 2021. Main outcome measures were the rate of implementation of molecular tumor board (MTB) recommended treatments and treatment response as assessed by disease control rate, objective response rate and PFS ratio. Out of the recruited patients, 412 (54.9% HR+/HER2-, 31.3% TNBC, 6.8% HR-/HER2+ and 7.0% HR+/HER2+) were reviewed in the MTB. An appropriate molecularly guided anti-cancer treatment as recommended by MTB was implemented in 183 (44.4%) patients. Gene expression and computationally derived composite biomarkers further expanded treatment options in up to every second patient as compared to genomic sequencing data alone. The outcome was assessed in 152 patients and showed a Disease Control Rate (DCR) of 58.6% and an Objective Response Rate (ORR) of 27.0%. One in three patients (32.8%) showed at least a 50% longer PFS with molecularly guided therapy compared to the previous standard therapy. Notably, 86.4% of the MTB-driven implementations were off-label. CATCH highlights the impact of whole-genome/exome in combination with RNA sequencing to detect clinically relevant biomarkers in mBC. Omics-guided targeted therapy in a real-world setting allows high treatment implementation rates yielding outcome benefit for one-third of the patients.

International Journal of CancerVol. 158(6)
German Cancer Research Center (DE), Heidelberg University (DE), University Hospital Heidelberg (DE), LMU Klinikum (DE), Düsseldorf University Hospital (DE), Integrated Oncology (United States) (US), National Center for Tumor Diseases (DE), Hopp Children's Cancer Center Heidelberg (DE), DKFZ-ZMBH Alliance (DE), Heidelberg Institute for Stem Cell Technology and Experimental Medicine (DE), University Hospital Cologne (DE), University Hospital Ulm (DE), Deutsches Konsortium für Translationale Krebsforschung (DE), Heinrich Heine University Düsseldorf (DE), Ludwig-Maximilians-Universität München (DE)
Deutsches Krebsforschungszentrum, Deutsche Krebshilfe
Openalex Percentile: Top 61%
Cancer Genomics and Diagnostics
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.